Retatrutide side effects, from the trial data

What this guide covers

Everything known about retatrutide's side effects comes from one 48-week Phase 2 trial. The GI profile, the heart-rate signal, the skin-sensitivity reports, and what nobody can know yet. This is patient education, not a substitute for the prescriber who knows your case. Generic names sit next to brand names throughout: semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound).

Key points

• Read this first: the data is Phase 2 data. Retatrutide is investigational, so its entire human side-effect record comes from controlled trials, chiefly the 338-person, 48-week Phase 2 obesity study published in NEJM and a similarly sized diabetes study in The Lancet. That cuts both ways. The data is high quality: randomized, placebo-controlled, systematically collected, better than the anecdote soup around most new drugs. And it is thin: a few hundred people followed for under a year cannot surface rare events or long-term effects. The approved GLP-1 drugs have millions of patient-years behind their labels; retatrutide has hundreds of patient-years, full stop.
• The GI profile: familiar, dose-dependent. The most common side effects were exactly what this drug class always produces: nausea first, then diarrhea, vomiting and constipation, mild to moderate for most, concentrated during dose escalation, and clearly dose-dependent, with the highest doses producing the most. Slower titration reduced them, which is why the trial protocols escalate gradually. Anyone who has read our guides on Ozempic nausea or diarrhea knows this playbook; retatrutide simply runs it with three hormones instead of one or two.
• The two retatrutide-specific signals. First, heart rate. Glucagon-receptor agonism raises it, and the trial measured an increase that peaked around the middle of the study and partially declined by week 48. For most healthy participants it was a number on a monitor rather than a symptom, but it is precisely the kind of signal that demands Phase 3's larger cardiovascular picture before anyone can call it benign. Second, skin sensitivity: a subset of participants reported unusual skin sensations, a finding distinctive enough that the investigators noted it. Neither stopped the program; both are open questions, and honest coverage says so.
• What nobody can know yet, and the gray-market multiplier. Unknowns at this stage: long-term effects past one year, rare events, interactions, effects in people the trial excluded, and whether the heart-rate signal matters clinically at scale. That is the normal state of a Phase 3 drug and the reason it is not approved. One more thing belongs in a side-effects article: every risk above was measured in supervised trials with verified drug, ECGs and structured titration. Gray-market 'reta' carries all of those risks plus unverified identity, purity and dose, with no monitoring. The side-effect profile of an unregulated vial is unknowable, and we do not link to anyone selling them.

Frequently asked questions